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Abstract 
Review on t(12;13)(p13;q12) ETV6/FLT3, with data 
on clinics, and the genes implicated. 
Clinics and pathology 
Disease 
Acute lymphoblastic leukemia (ALL) and myeloid 
malignancies are described in cases of 
t(12;13)(p13;q12) 
Note 
The translocation t(12;13)(p13;q12) is molecularly 
heterogeneous:  
The t(12;13)(p13;q12) with ETV6 and FLT3 
involvement, herein described, was found in three 
cases of myeloproliferative neoplasm (MPN) with 
eosinophilia (Vu et al., 2006; Walz et al., 2011). 
On the other hand, a t(12;13)(p13;q12) ETV6/CDX2 
has been described in another case (Chase et al., 
1999). 
Finally, other cases of t(12;13)(p13;q12) without 
molecular ascertainment may or may not involve 
FLT3, CDX2, or even ETV6. 
Epidemiology 
All together, eleven cases of t(12;13)(p13;q12) were 
described. 
Clinics 
Three cases of t(12;13)(p13;q12) ETV6/FLT3 are 
reported: 
A female patient aged 68 years, with a MPD with  
eosinophilia; she died 21 months after diagnosis. 
A 60-year old man with a MPN with 
hypereosinophilia in accelerated phase; he died soon 
after diagnosis of infection and pancytopenia. 
A 29-year old man who developed MPN with 
hypereosinophilia four weeks after autologous stem 
cell transplantation following a T-lymphoblastic 
lymphoma; he died 5 weeks after diagnosis of MPN. 
Another case presents with a similar phenotype: a 49 
year-old male patient, also with a MPN with 
eosinophilia; he died 11 months after diagnosis (and 
with a history of leukocytosis for last two years 
before diagnosis).  
No molecular analysis was performed (Chiyoda et 
al., 1994).  
The case with ETV6/CDX2 involvement was a 66 
year old male patient with M1 acute myeloid 
leukaemia (AML); he died 40 months after 
diagnosis.  
The six other known patients with a 
t(12;13)(p13;q12) were two children and one 17 
year-old female patient with acute lymphoblastic 
leukemia (ALL) (Keene et al., 1987; Wlodarska et 
al., 1998; Heerema et al., 2000) and three adult 
patients with myeloid diseases (one refractory 
anemia with excess of blasts (RAEB) and two 
AMLs; one of which was a treatment-related AML 
(t-AML)) (Knapp et al., 1985; Tosi et al., 1998; 
Clavio et al., 2001). 
Cytology 
All three patients with ETV6/FLT3 had 
myeloproliferative neoplasm with eosinophilia. 
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Cytogenetics 
Cytogenetics morphological 
The t(12;13)(p13;q12) was the sole anomaly in six 
cases (three MPD with eosinophilia, one ALL, the 
RAEB and a M0-AML).  
The t(12;13)(p13;q12) was accompanied with -5 and 
-7 in the t-AML, and with major karyotypic 
anomalies (MAKA) in the CD10+ ALL in the 17 
year-old female patient and the MPN in the 60 year-
old male patient. 
Genes involved and 
proteins 
Note 
In three patients, the ETV6/FLT3 implication was 
found (Vu et al., 2006; Walz et al., 2011). Following 
the first report, transgenic mice expressing ETV6-
FLT3 were used (Baldwin et al., 2007).  
Expression of the fusion protein in the transgenic 
mice was found in spleen, bone marrow, thymus, and 
liver.  
A significant increase in the number of CFU-GM, 
BFU-E, CFU-S and CFU-GEMM was produced.  
Mice developed MPD with a high incidence but did 
not succumbed to leukemia (Baldwin et al., 2007). 
ETV6 
Location 
12p13 
Note 
The ETV6 gene encodes a transcription factor 
frequently rearranged in myeloid and lymphoid 
leukemias. 
DNA/RNA 
The ETV6 gene spans a region of less than 250 kb at 
band 12p13.1 and consists of 8 exons.  
There are two start codons, one (exon 1a starting at 
codon 1) located at the beginning of the gene and 
another alternative (exon 1b starting at codon 43) 
upstream of exon 3. 
Protein 
The ETV6 protein (452 amino acids) contains two 
major domains, the HLH (helix-loop-helix) and ETS 
domains.  
The HLH domain, also referred to as the pointed or 
sterile alpha motif domain, is encoded by exons 3 
and 4 and functions as a homo-oligodimerization 
domain.  
The ETS domain, encoded by exons 6 through 8, is 
responsible for sequence specific DNA-binding and 
protein-protein interaction.  
Transcriptional regulator; involved in bone marrow 
hematopoiesis. 
FLT3 
Location 
13q12 
Note 
FLT3 is one of the most frequently mutated genes in 
hematologic malignancies, being found in about 
30% of AML patients and rarely in ALL patients 
(Gilliland and Griffin, 2002; Stirewalt and Radich, 
2003). 
DNA/RNA 
The FLT3 gene spans a region of 97 kb and consists 
of 24 exons. 
Protein 
The FLT3 gene is a member of the receptor tyrosine 
kinase subclass III family of genes.  
It encodes a protein structurally related to the 
receptors for platelet derived growth factor. Contains 
five immunoglobulin-like domains in the 
extracellular domain involved in protein-ligand 
interaction, a transmembrane domain, and an 
intracellular tyrosine kinase domain.  
Dimerization induces kinase domain activation, 
leading to the activation of intracellular signalling 
pathways. Expressed on early hemopoietic 
progenitor cells. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Both ETV6/FLT3 and FLT3/ETV6 transcripts were 
detected. However, FLT3/ETV6 transcripts were out 
of frame. Various in frame fusion products of 
ETV6/FLT3 were found.  
Fusion of exon 5 of ETV6 5' term to exon 14 of FLT3 
3' term (and exon 4 and 16 in one transcript) (Vu et 
al., 2006). 
In-frame fusion genes were observed between exon 
4 or 5 of ETV6 and exon 14 of FLT3 (Walz et al., 
2011). 
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Schematic diagram of the ETV6, FLT3 and ETV6-FLT3 proteins. 
 
 
Fusion protein 
Description 
N-term Helix-loop-helix (HLH) oligodimerization 
domain of ETV6 fused to the transmembrane and 
tyrosine kinase domains of FLT3. 
Oncogenesis 
Constitutive tyrosine kinase activation of FLT3. 
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